Premium
Genetic variations of CD 36 and low platelet CD 36 expression – a risk factor for lipemic plasma donation in Taiwanese apheresis donors
Author(s) -
Lo S.C.,
Lin K.H.,
Hsieh H.H.,
Lin D.T.,
Hu C.Y.
Publication year - 2016
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/vox.12356
Subject(s) - apheresis , immunology , population , platelet , plateletpheresis , chemistry , monocyte , medicine , andrology , environmental health
Background New CD 36 mutations are constantly being identified, although no study has specifically targeted a Taiwanese population. CD 36 deficiency can result in dyslipid state and slow clearance of chylomicron. This could be linked to more frequent lipemic donations. Study Design and Methods We used flow cytometric methods to study the CD 36 deficiency in 640 regular volunteer platelet apheresis donors from Taipei blood centre. The coding exons of CD 36 gene were sequenced in CD 36‐deficient individuals, and the allele frequencies of CD 36 variants were determined in the larger population by mutation‐specific PCR and oligonucleotide hybridization. Visual inspection of lipemic plasma was routinely performed on samples taken before commencement of apheresis. Individuals found to have lipemic plasma are deferred until next donation. We investigated the link between positive lipemic deferral record and low platelet CD 36 expression status. Results We found four donors (0·6%) with type I CD 36 deficiency (both platelets and monocytes CD 36 null ) and six (1·0%) with type II CD 36 deficiency ( PLT : CD 36 null , monocyte: CD 36 low ). Six CD 36 genetic variants were identified, two of them were novel, all but one are found exclusively in CD 36 null and CD 36 low expressors. Subjects with CD 36 genetic variants also displayed deficient or reduced CD 36 on monocytes. Donors with null or low PLT CD 36 expression were more likely to have a lipemic deferral record than control subjects with normal PLT CD 36 expression ( X 2 = 27·36, odds ratio = 2·6, 95% conference interval: 1·8–3·8, P < 0·0001). Conclusion Through this study, we established a donor registry to supply CD 36‐negative platelets for patients in need.